EMAIL THIS PAGE TO A FRIEND

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

Evaluation of the matrix effect of different sample matrices for 33 pharmaceuticals by post-column infusion.


PMID 26210586

Abstract

Matrix effects that occur during quantitative measurement by liquid chromatography mass spectrometry specifically when using electrospray ionization are a widely recognized phenomenon. Sample matrix compounds affect the ionization process of the target analytes, lead to a low signal response, and flawed analytical results. How these matrix compounds directly influence the ionization process has not yet been completely understood. In the present study, we determined the matrix effect for 33 pharmaceutical substances in sample extracts of urine, plasma and wastewater. Most of the investigated substances were subject to a signal suppression effect. Only for a small subset of the compounds we detected a signal enhancement effect. We investigated the matrix effect profiles in detail to disentangle the influence of different matrices and to correlate the impact of specific components and groups of the analyzed extract in suppressing or enhancing effects in the profile. Most signal suppression effects were detected in the first half of the chromatographic run-time for the matrix extracts of urine and wastewater. The observed effects are caused by high mass flow of salts and other diverse matrix components that were contained in high concentrations in those biological matrices. We also found signal suppression in the matrix effect profile of plasma samples over a wide time range during the chromatographic separation that were associated with a high content of triglycerides of diverse carbohydrate chain lengths. Here, we provide a broader picture of how 33 substances were influenced during analysis. Our results imply that a high number of the investigated substances had comparable effects of matrix compounds, despite differences in their chemical structure.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

D-091
10,11-Dihydro-10-Hydroxycarbamazepine solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material
C15H14N2O2
A-072
Atenolol solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material
C14H22N2O3
C8981
Carbamazepine, meets USP testing specifications
C15H12N2O
C-053
Carbamazepine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material
C15H12N2O
C6305
Clozapine
C18H19ClN4
C171
Clozapine, solid
C18H19ClN4
C-059
Clozapine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material
C18H19ClN4
F-031
Fluconazole solution, 2.0 mg/mL in methanol, ampule of 1 mL, certified reference material
C13H12F2N6O
G154
Gabapentin, solid
C9H17NO2
G-007
Gabapentin solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material
C9H17NO2
G007
Guvacine hydrochloride, ≥97% (NMR), solid
C6H9NO2 · HCl
H1512
Haloperidol, powder
C21H23ClFNO2
H100
Haloperidol
C21H23ClFNO2
H-030
Haloperidol solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material
C21H23ClFNO2
L3791
Lamotrigine, ≥98%, powder
C9H7Cl2N5
L-019
Lamotrigine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material
C9H7Cl2N5
L8668
Levetiracetam, ≥98% (HPLC)
C8H14N2O2
L-020
Levetiracetam solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material
C8H14N2O2
M0443
Mirtazapine, ≥98% (HPLC)
C17H19N3
M-128
Mirtazapine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material
C17H19N3
V-007
O-Desmethylvenlafaxine solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material
C16H25NO2
O1141
Olanzapine, ≥98% (HPLC)
C17H20N4S
O-024
Olanzapine solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material
C17H20N4S
O3764
Oxcarbazepine, ≥98% (HPLC), solid
C15H12N2O2
PZ0010
Pregabalin, ≥97% (NMR)
C8H17NO2
P-066
Pregabalin solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material
C8H17NO2
P-075
Primidone solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material
C12H14N2O2
R-006
Risperidone solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material
C23H27FN4O2
T-039
Topiramate solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material
C12H21NO8S
T-904
Trimipramine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material
C20H26N2